Phesgo (Pertuzumab/Trastuzumab)

Phesgo is manufactured in Switzerland and shipped by our pharmacy in India by courier.

Information About Phesgo (Pertuzumab/Trastuzumab)

Phesgo is a combination medication containing pertuzumab and trastuzumab, both of which are monoclonal antibodies that target the HER2 (human epidermal growth factor receptor 2) protein. This combination is used to treat HER2-positive breast cancer, a type of cancer that is driven by the overexpression of the HER2 protein on the surface of cancer cells. Phesgo is an innovative formulation that combines both drugs in a single subcutaneous injection, making it more convenient for patients compared to the traditional intravenous (IV) administration of these therapies.

Product Highlights

• Phesgo is indicated for the treatment of HER2-positive breast cancer, a type of cancer that overproduces the HER2 protein.
• For early-stage HER2-positive breast cancer in combination with chemotherapy, following surgery to reduce the risk of recurrence.
• Used for HER2-positive metastatic breast cancer, either alone or in combination with chemotherapy, to inhibit tumor growth and improve survival outcomes.
• Used before surgery in combination with chemotherapy to shrink tumors and improve surgical outcomes in patients with early-stage HER2-positive breast cancer.

Key Ingredient

• Pertuzumab
• Trastuzumab

Key Benefits

• The combination of pertuzumab and trastuzumab offers a potent treatment for HER2-positive breast cancer, leading to improved survival and progression-free survival rates.
• Phesgo is delivered via subcutaneous injection, which is faster and more convenient than intravenous infusion, requiring less time in the clinic.
• Clinical trials have shown that using Phesgo significantly improves outcomes in both early-stage and metastatic HER2-positive breast cancer compared to previous treatments.
• The combination of two HER2-targeted therapies (pertuzumab and trastuzumab) provides a synergistic effect, leading to enhanced tumor suppression.

Direction of Use

• Phesgo is administered as a subcutaneous injection by a healthcare provider, typically in the upper arm or abdomen.
• The recommended dose of Phesgo is determined by the patient's body weight.The injection is usually given every 3 weeks after an initial loading dose, which is higher to rapidly achieve therapeutic levels.
• Phesgo is commonly administered alongside chemotherapy for optimal treatment of HER2-positive breast cancer.
• After the initial dose, it is typically given every 3 weeks, but the schedule may vary depending on the treatment plan prescribed by the healthcare provider.

Safety Concerns

• Although Phesgo is given as a subcutaneous injection, some patients may experience local reactions such as redness, pain, or swelling at the injection site. Infusion-related reactions (though more common with IV formulations) can still occur and may include fever, chills, or difficulty breathing.
• Both pertuzumab and trastuzumab can cause heart-related issues, including reduced heart function (left ventricular dysfunction) or heart failure. Patients should undergo regular monitoring of their heart function during treatment.
• The combination therapy may suppress immune function, increasing the risk of infections. Patients should be monitored for signs of infection and treated promptly if needed.
• Phesgo may harm a developing fetus, and its use is contraindicated in pregnancy. Women of childbearing age should use effective contraception during treatment and for some time after completing therapy.
• Severe allergic reactions (anaphylaxis) are rare but possible. Patients should be monitored for signs of severe allergic reactions, particularly after the first injection.
• Some patients may experience a decrease in white blood cells, increasing the risk of infections. Regular blood tests are needed to track white blood cell counts.

Avoid Phesgo (Pertuzumab/Trastuzumab) If

• Phesgo is contraindicated in pregnancy due to the risk of fetal harm. It should not be used during pregnancy or lactation. Women should avoid becoming pregnant during treatment and for at least 7 months after the last dose.
• Do not use Phesgo if you are allergic to pertuzumab, trastuzumab, or any of its ingredients.
• If you have a history of heart failure or significant heart problems, Phesgo may not be appropriate, as it can worsen cardiac function.
• If you have an active infection or severe immune system suppression, you should avoid Phesgo until the infection is resolved and your immune status is stabilized.
• While not a direct contraindication, caution should be used in patients with liver or kidney problems as these conditions can affect how the medication is processed in the body.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.